Head to Head Review: Biohaven (NYSE:BHVN) versus Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Biohaven (NYSE:BHVN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Damora Therapeutics, Inc. Common Stock and Biohaven, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1	1	8	2	2.92
Biohaven	2	4	9	2	2.65

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $44.00, suggesting a potential upside of 40.17%. Biohaven has a consensus target price of $21.75, suggesting a potential upside of 49.28%. Given Biohaven’s higher possible upside, analysts plainly believe Biohaven is more favorable than Damora Therapeutics, Inc. Common Stock.

Insider and Institutional Ownership

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Damora Therapeutics, Inc. Common Stock and Biohaven”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84 million	($5.58)	-5.63
Biohaven	N/A	N/A	-$738.82 million	($4.64)	-3.14

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Damora Therapeutics, Inc. Common Stock and Biohaven’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-375.57%	-97.74%
Biohaven	N/A	-1,070.80%	-132.67%

Risk & Volatility

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

Summary

Biohaven beats Damora Therapeutics, Inc. Common Stock on 6 of the 11 factors compared between the two stocks.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.